Publication:
The effect of serum levetiracetam concentrations on therapeutic response and IL1-beta concentration in patients with epilepsy

Simple item page
dc.contributor.authorONAT, FİLİZ
dc.contributor.authorsGulcebi, Medine I.; Kendirli, Tansel; Turgan, Zehra Asik; Patsalos, Philip N.; Onat, Filiz Yilmaz
dc.date.accessioned2022-03-14T10:17:10Z
dc.date.available2022-03-14T10:17:10Z
dc.date.issued2018-12
dc.description.abstractObjective: Assessment of the relevance between serum drug concentration to its therapeutic response is a valid monitoring strategy for the clinical efficacy of antiepileptic drugs (AEDs). Levetiracetam (LEV) is a broad spectrum AED with a possible anti-inflammatory effect. We aimed to determine the relationship between LEV concentrations and its therapeutic response, and the effect of LEV on IL1-beta concentrations in patients with epilepsy. Methods: Patients on monotherapy (n = 7) or polytherapy (n = 15) with LEV for their seizures management were included. Blood samples of each patient were collected: just before LEV intake, 1 h, 2 h, 4 h and 8 h following the last dose. Serum LEV concentrations were measured by liquid chromatography mass spectrometry and IL1-beta concentrations by chemiluminescent immunometric assay. Concentration to dose (C/D) ratio values was used for analyses. LEV concentrations were compared between responders (<= 1 seizure/month) and non responders (> 1 seizure/month) and patients with or without adverse reactions. IL1-beta concentrations before and at 2 h following LEV ingestion were compared in order to detect the effect of the increase in serum LEV concentration on IL1-beta. Results: Although there was no change in LEV (C/D) ratio or LEV maximum concentration (Cmax)/D ratio of the responders and non-responders, the C/D ratio following 1 h of LEV intake (2.17 +/- 0.59 kg.day/L) and Cmax/D ratio (2.25 +/- 0.56 kg.day/L) in the patients with adverse effects was significantly higher than for the patients without adverse effects (1.09 +/- 0.12 kg.day/L and 1.49 +/- 0.14 kg.day/L respectively). A statistically significant decrease was found in the IL1-beta concentration to LEV (C/D) ratio with the increase in LEV concentration in patients on LEV monotherapy. Conclusion: The possible relationship between LEV Cmax and its therapeutic response or IL1-beta concentrations may be an importance indication of LEV antiepileptic efficacy. Consequently, monitoring LEV Cmax values may enhance LEV adherence because patients would be less likely to develop adverse effects.
dc.identifier.doi10.1016/j.eplepsyres.2018.09.015
dc.identifier.eissn1872-6844
dc.identifier.issn0920-1211
dc.identifier.pubmed30326332
dc.identifier.urihttps://hdl.handle.net/11424/244304
dc.identifier.wosWOS:000452567700003
dc.language.isoeng
dc.publisherELSEVIER SCIENCE BV
dc.relation.ispartofEPILEPSY RESEARCH
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectAntiepileptic drugs
dc.subjectSeizure frequency
dc.subjectAdverse effect
dc.subjectCytokine
dc.subjectANTIEPILEPTIC DRUGS
dc.subjectILAE-COMMISSION
dc.subjectCHILDREN
dc.subjectLAMOTRIGINE
dc.subjectEFFICACY
dc.titleThe effect of serum levetiracetam concentrations on therapeutic response and IL1-beta concentration in patients with epilepsy
dc.typearticle
dspace.entity.typePublication
local.avesis.id95b54ee4-1bd9-42f9-a644-4ca7c2d8ebb9
local.import.packageSS16
local.indexed.atWOS
local.indexed.atSCOPUS
local.journal.numberofpages6
local.journal.quartileQ3
oaire.citation.endPage22
oaire.citation.startPage17
oaire.citation.titleEPILEPSY RESEARCH
oaire.citation.volume148
relation.isAuthorOfPublicationc359dea3-046f-4397-90d5-62e4bfc31869
relation.isAuthorOfPublication.latestForDiscoveryc359dea3-046f-4397-90d5-62e4bfc31869

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Gulcebi et al. - 2018 - The effect of serum levetiracetam concentrations o.pdf
Size:
578.09 KB
Format:
Adobe Portable Document Format
Download

Collections

Research Outputs